ES2945782R1 - Biomarcadores predictivos de autoinmunidad en pacientes tratados con alemtuzumab. - Google Patents

Biomarcadores predictivos de autoinmunidad en pacientes tratados con alemtuzumab. Download PDF

Info

Publication number
ES2945782R1
ES2945782R1 ES202390028A ES202390028A ES2945782R1 ES 2945782 R1 ES2945782 R1 ES 2945782R1 ES 202390028 A ES202390028 A ES 202390028A ES 202390028 A ES202390028 A ES 202390028A ES 2945782 R1 ES2945782 R1 ES 2945782R1
Authority
ES
Spain
Prior art keywords
alemtuzumab
autoimmunity
patients treated
predictive biomarkers
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES202390028A
Other languages
English (en)
Other versions
ES2945782A2 (es
Inventor
Guimerans Luisa María Villar
Delgado Paulette Esperanza Walo
Heras Silvia Medina
Laguillo Enrique Monreal
Fransa Lucienne Costa-Frossard
De La Maza Cantero Susana Sainz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon Y Cajal
Original Assignee
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon Y Cajal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon Y Cajal filed Critical Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon Y Cajal
Publication of ES2945782A2 publication Critical patent/ES2945782A2/es
Publication of ES2945782R1 publication Critical patent/ES2945782R1/es
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES202390028A 2020-11-13 2021-09-29 Biomarcadores predictivos de autoinmunidad en pacientes tratados con alemtuzumab. Pending ES2945782R1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382988.2A EP4001919A1 (en) 2020-11-13 2020-11-13 Predictive biomarkers of autoimmunity in patients treated with alemtuzumab
PCT/EP2021/076872 WO2022100920A1 (en) 2020-11-13 2021-09-29 Predictive biomarkers of autoimmunity in patients treated with alemtuzumab

Publications (2)

Publication Number Publication Date
ES2945782A2 ES2945782A2 (es) 2023-07-07
ES2945782R1 true ES2945782R1 (es) 2024-03-08

Family

ID=73642818

Family Applications (1)

Application Number Title Priority Date Filing Date
ES202390028A Pending ES2945782R1 (es) 2020-11-13 2021-09-29 Biomarcadores predictivos de autoinmunidad en pacientes tratados con alemtuzumab.

Country Status (3)

Country Link
EP (1) EP4001919A1 (es)
ES (1) ES2945782R1 (es)
WO (1) WO2022100920A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100136587A1 (en) * 2007-02-16 2010-06-03 Margolin David H Method of Identifying Risk for Thyroid Disorder
EP3241910B1 (en) * 2008-10-08 2020-01-08 Cambridge Enterprise Limited Methods for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis
WO2016063253A1 (en) * 2014-10-23 2016-04-28 Pontificia Universidad Católica De Chile A method and a kit to predict prognosis in patients with relapsing remitting multiple sclerosis and poor prognosis: a decision making tool for prescription of treatment
EP3631463A1 (en) * 2017-06-02 2020-04-08 Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal Method for monitoring and/or predicting the efficacy of treatment in a multiple sclerosis patient
WO2020004369A1 (ja) * 2018-06-29 2020-01-02 学校法人東京女子医科大学 心電図画像を用いた機械学習による心電図診断装置

Also Published As

Publication number Publication date
EP4001919A1 (en) 2022-05-25
ES2945782A2 (es) 2023-07-07
WO2022100920A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
SG11202104882WA (en) Machine learning disease prediction and treatment prioritization
BR112018075288A2 (pt) métodos para diagnóstico de infecções bacterianas e virais
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
WO2015111008A3 (en) Biomarkers predictive of muscle atrophy, method and use
CL2017003069A1 (es) Métodos para diagnosticar y tratar el cáncer.
BR112018008357A2 (pt) mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas
BR112022002370A2 (pt) Método de nova seleção de relé, dispositivo e meio.
PH12020551683A1 (en) Biomarkers for graft-versus-host disease
ECSP11010872A (es) Métodos, sistemas y productos para predecir la respuesta de las células tumorales a un agente terapéutico y tratar un paciente de acuerdo con la respuesta predicha
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
GB201810190D0 (en) Prognostic and treatment response predictive method
BR112017022320A2 (pt) métodos para tratamento de câncer de pulmão
BR112018013399A2 (pt) unidade e método de entrega de substância agroquímica e processo para produção da unidade de entrega
EA201792669A1 (ru) Igfbp3 и его применение
BR112018014762A2 (pt) método de tratamento da doença de alzheimer (da) precoce
EP3746087A4 (en) METHODS FOR EARLY PREDICTION AND PREVENTION OF PRE-ECLAMPSIA USING BIOMARKERS ASSOCIATED WITH CIRCULATING MICROPARTICLES
HK1250751A1 (zh) 基於脂肪組織樣本預測和/或診斷疾病的方法及方法套件
DK3161165T3 (da) Fremgangsmåde til diagnosticering af subklinisk og klinisk akut afstødning ved analyse af prædiktive gensæt, terapeutisk middel til anvendelse ved behandlingen og kits til at bestemme ekspressionen
ES2945782R1 (es) Biomarcadores predictivos de autoinmunidad en pacientes tratados con alemtuzumab.
EA201501137A1 (ru) Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac
MX2015009726A (es) Metodo para la prediccion de la aparicion de sintomas extrapiramidales (sep) inducidos por un tratamiento con antipsicoticos.
BR112017018518A2 (pt) biomarcadores previstos de resposta clínica para o tratamento de imunoglobulina antilps
EA201891693A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови
BR112021018441A2 (pt) Método para tratamento de psoríase em indivíduos pediátricos com anticorpo anti-il12/il23

Legal Events

Date Code Title Description
BA2A Patent application published

Ref document number: 2945782

Country of ref document: ES

Kind code of ref document: A2

Effective date: 20230707

EC2A Search report published

Ref document number: 2945782

Country of ref document: ES

Kind code of ref document: R1

Effective date: 20240301